Topical antifungals, although often effective, are being discouraged in the early treatment of seborrheic dermatitis now that ...

Among the FDA’s pending decisions for this quarter are Vertex’s non-opioid pain drug and Sanofi’s RNA interference therapy ...

Many leading stocks flashed buy signals Friday as the market rebounded, including Nvidia. CEO Jensen Huang gives a key speech ...

BMS-986484 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Non-Small Cell Lung Cancer.

Zolacabtagene autoleucel is under clinical development by Bristol-Myers Squibb and currently in Phase I for Marginal Zone B-cell Lymphoma.

PLTR stock has jumped 340% in 2024 with much of the gain coming after Trump's election win amid views government AI ...

Regeneron Pharmaceuticals is a strong investment with robust growth potential, fueled by FDA approvals and resilient market ...

The FDA approved subcutaneous nivolumab for solid tumors, tiselizumab for advanced gastric and GEJ cancers, and key 2024 breast cancer breakthroughs are reviewed. Experts provide perspective on ...